

# The Roche respiratory testing continuum

## Why Roche?




High quality tests across the continuum of care



A trusted partner now and in the future




Solutions **and** services that you can count on



### cobas® e immunoassay analyser

#### Versatile & specific


Elecsys® immunoassays for fast SARS-CoV-2 detection and assessment of humoral and cellular adaptive immune response for every throughput need<sup>1</sup>



### cobas® x800 systems

#### High efficiency

Testing efficiencies for medium to high-volume, focused and flexible multiplex PCR testing<sup>2</sup>



### cobas® eplex system

#### Comprehensive & fast

Fast, comprehensive testing to support differential diagnosis especially for high risk & hospitalized patients<sup>3</sup>



### cobas® liat system

#### Targeted & near patient

Multi- and single- target assays with results in minutes<sup>4</sup>

- Results in 18 min
- Small sample volume
- Wide range of specimen types
- High sensitivity and specificity

- Consolidate high volume PCR testing
- Automation eliminates manual steps to reduce hands-on time and error
- Industry leading instruments integrated into a single solution


- Syndromic diagnosis because symptoms are often overlapping
- Results in ~90 min
- Rapid, actionable results for high-risk patients

- Confidence with gold standard PCR technology
- Quick results in 20 minutes or less
- Control with strategic connectivity

# An overview of the Roche respiratory testing continuum

	<b>Ease of use</b>	<b>Time to result (assay dependent)</b>	<b>Technology</b>	<b>Available respiratory tests*</b>	<b>Benefits</b>
<b>cobas® x800 systems<sup>2</sup></b>	<ul style="list-style-type: none"> <li>Pre-calibrated, ready to use reagents</li> <li>Minimal and intuitive technician interactions – simply load and go</li> <li>Integrates with lab automations designed specifically for molecular workflows</li> </ul>	Up to 96 results in ~3 hours	Gold standard PCR technology	<b>cobas®</b> MTB <sup>3</sup> ; <b>cobas®</b> MAI <sup>3</sup> ; <b>cobas®</b> SARS-CoV-2 Qualitative; <b>cobas®</b> SARS-CoV-2 & Influenza A/B (v2) <sup>EUA, CE-IVD</sup> ; <b>cobas®</b> SARS-CoV-2 Duo <sup>EUA, CE-IVD</sup> ; <b>cobas®</b> Respiratory flex <sup>c</sup>	<ul style="list-style-type: none"> <li>The fully automated <b>cobas®</b> x800 Systems offer focused and first of its kind flexible reliable respiratory testing with fast time to results, the highest throughput and the longest walk-away time available among automated molecular platforms<sup>6</sup></li> </ul>
<b>cobas® eplex system<sup>3</sup></b>	<ul style="list-style-type: none"> <li>&lt; 1 min hands-on time</li> <li>Random &amp; continuous access</li> <li>Modular &amp; scalable</li> </ul>	~90 min	Multiplex PCR, electrowetting & eSensor detection technologies	<b>cobas® eplex</b> respiratory pathogen panel 2 (EUA, CEIVD) (>20 viral and bacterial targets for the most common respiratory pathogens)	<ul style="list-style-type: none"> <li>Perform testing on all shifts</li> <li>Quick results for optimized patient care</li> <li>Comprehensive results: 20+ pathogens</li> </ul>
<b>cobas® liat system<sup>4</sup></b>	<ul style="list-style-type: none"> <li>Less than 1 min hands-on time</li> <li>Intuitive, easy to use interface</li> <li>Small design made to fit any clinic, urgent care or satellite location</li> </ul>	20 mins or less**	Gold standard PCR technology	<b>cobas®</b> SARS-CoV-2 <b>cobas®</b> SARS-CoV-2 & Influenza A/B <b>cobas®</b> Influenza A/B & RSV <b>cobas®</b> Strep A <b>cobas®</b> Cdiff	<ul style="list-style-type: none"> <li><b>Quick</b> test results</li> <li>PCR-reliable <b>confidence</b></li> <li>Strategically connected <b>control</b></li> </ul>
<b>cobas® e immunoassay analysers<sup>1</sup></b>	<ul style="list-style-type: none"> <li>Modular and scalable</li> <li>Minimal operator intervention</li> <li>Consolidated test offering</li> </ul>	18 min	ECLIA	Elecsys® Anti-SARS-CoV-2 <sup>a*</sup> Elecsys® Anti-SARS-CoV-2 S <sup>a,b*</sup> Elecsys® SARS-CoV-2 Antigen Elecsys® IGRA SARS-CoV-2	<ul style="list-style-type: none"> <li>High sensitivity and specificity<sup>1</sup></li> <li>Low sample volume<sup>1</sup></li> <li>High throughput</li> <li>Detection of sustained antibody response<sup>3</sup></li> <li>High agreement with virus neutralizing capacity<sup>6</sup></li> </ul>

## Child with respiratory symptoms



### Possible Roche solutions across the continuum of care

<b>Solution</b>	<b>Situational benefits</b>	<b>Comparative benefits</b>
<b>cobas® liat system<sup>4</sup></b>	Quick molecular testing for influenza, SARS-CoV-2, RSV (likely causes of infection).	20 min Up to 4 targets (viruses)
<b>cobas® eplex system<sup>5</sup></b>	Fast results and comprehensive coverage of common respiratory pathogens that can cause severe illness or complications in high-risk patients. Identification of co-infections can be critical in patient management.	~90 min >20 targets (bacteria and viruses)
<b>cobas® x800 systems<sup>6</sup></b>	Flexible, efficient multiplex respiratory testing for common viral pathogens available in centralized setting.	~3 hrs Up to 12 targets (viruses)
<b>cobas® e immunoassay analysers<sup>1</sup></b>	Test for the detection of the SARS-CoV-2 antigen. Less expensive, high throughput. Test for SARS-CoV-2 anti-N antibodies to evaluate for MIS-C following prior viral (possibly SARS-CoV-2) infection.	18 min (+ transport) SARS-CoV-2 only

EUA: Emergency Use Authorization; ECLIA: electrochemiluminescence immunoassay

\*Other tests are available – please see system specific sites for full menu; \*\*Turnaround time varies by assay

<sup>a</sup> In development for **cobas®** 5800 system; <sup>b</sup> Product in development. Not available for sale; <sup>c</sup> Product launched with CE mark only; not available for sale in the US.

## Otherwise healthy adult with respiratory symptoms



Usually healthy adult presents with respiratory infection symptoms at a rural clinic.



Multiple options available at rural setting all meeting different needs. Resourcing, cost, and urgency are important factors.



Increased difficulty breathing and goes to Emergency Department. Could be worsening infection, new co-infection or pneumonia.

### Possible Roche solutions across the continuum of care

Solution	Situational benefits	Comparative benefits
<b>cobas® liat system<sup>4</sup></b>	Quick molecular testing for influenza, Strep A, SARS-CoV-2, and/or RSV applicable for outpatient and Emergency Department setting.	20 min Up to 4 targets (bacteria or viruses)
<b>cobas® eplex system<sup>5</sup></b>	Comprehensive pathogen coverage in a single test can identify infections beyond influenza, SARS-CoV-2, and RSV. Co-infection detection could be impactful if patient continues to get sicker.	~90 min >20 targets (bacteria and viruses)
<b>cobas® x800 systems<sup>6</sup></b>	Flexible, efficient test for multiple viruses either as an outpatient send out test or from the Emergency Department. Option to test up to 12 viral targets using flexible ordering options.	~3 hrs Up to 12 targets (viruses)
<b>cobas® e immunoassay analysers<sup>1</sup></b>	Centralized, automated SARS-CoV-2 antigen testing. Less expensive, high throughput.	18 min (+ transport) SARS-CoV-2 only

## Respiratory symptoms at the Emergency Department



Usually healthy patient presents with respiratory symptoms at the Emergency Department.



They are tested for various respiratory infections. In the Emergency Department, accuracy and throughput is a priority to cope with the high volume of winter respiratory issues.



Based on their results, the patient is appropriately isolated and treated.

### Possible Roche solutions across the continuum of care

Solution	Situational benefits	Comparative benefits
<b>cobas® liat system<sup>4</sup></b>	Fast molecular testing for influenza, Strep A, SARS-CoV-2, and/or RSV applicable for outpatient and Emergency Department setting. Compact size gives flexibility to move where it's needed most.	20 min 1-4 targets (bacteria or viruses)
<b>cobas® eplex system<sup>5</sup></b>	Comprehensive pathogen coverage in a single test can identify infections beyond influenza, SARS-CoV-2, and RSV and also co-infections. Results can be used to guide decision to admit or discharge patient and isolation requirements if admitted.	~90 min >20 targets (bacteria and viruses)
<b>cobas® x800 systems<sup>6</sup></b>	Flexible, efficient test for multiple viruses either as an outpatient send out test or from the Emergency Department. Option to test up to 12 viral targets using flexible ordering options.	~3 hrs Up to 12 targets (viruses)
<b>cobas® e immunoassay analysers<sup>1</sup></b>	Centralized, automated SARS-CoV-2 antigen testing. Less expensive, high throughput.	18 min (+ transport) SARS-CoV-2 only

# Vulnerable patients in hospital



An elderly patient is in hospital for a scheduled hip replacement. On the day of the surgery, she is experiencing breathing difficulties.



Influenza is suspected, and the patient is tested before the scheduled start time of her surgery.



The patient is isolated and treated, and her surgery is postponed until she has recovered.

## Possible Roche solutions across the continuum of care

Solution	Situational benefits	Comparative benefits
<b>cobas® liat system<sup>4</sup></b>	Fast molecular testing for influenza, Strep A, SARS-CoV-2, and/or RSV applicable for outpatient and Emergency Department setting. Quick testing reduces the time patients need to spend in isolation.	20 min 1-4 targets (bacteria or viruses)
<b>cobas® eplex system<sup>5</sup></b>	Comprehensive coverage can identify infections beyond influenza, SARS-CoV-2, and RSV and even co-infections, which is especially relevant in an elderly patient who is at higher risk for severe illness. Results can be used to guide isolation recommendations to prevent spread of infection to other patients.	~90 min >20 targets (bacteria and viruses)
<b>cobas® x800 systems<sup>6</sup></b>	Flexible, efficient test for multiple viruses either as an outpatient send out test or from the Emergency Department. Option to test up to 12 viral targets using flexible ordering options.	~3 hrs Up to 12 targets (viruses)
<b>cobas® e immunoassay analysers<sup>1</sup></b>	Centralized, automated SARS-CoV-2 antigen testing. Less expensive, high throughput.	18 min (+ transport) SARS-CoV-2 only

EUA: Emergency Use Authorization; ECLIA: electrochemiluminescence immunoassay

\*Other tests are available – please see system specific sites for full menu; \*\*Turnaround time varies by assay

<sup>a</sup> In development for **cobas®** 5800 system; <sup>b</sup> Product in development. Not available for sale; <sup>c</sup> Product launched with CE mark only; not available for sale in the US.

## References

1. **Elecsys®** Anti-SARS-CoV-2 (200), Package Insert, V5, 2024.  
**Elecsys®** Anti-SARS-CoV-2 (300), Package Insert, V4, 2022.  
**Elecsys®** Anti-SARS-CoV-2 S (200), Package Insert, V4, 2024.  
**Elecsys®** Anti-SARS-CoV-2 S (300), Package Insert, V5, 2023.  
**Elecsys®** SARS-CoV-2 Antigen (200), Package Insert, V2, 2024.  
**Elecsys®** SARS-CoV-2 Antigen (300), Package Insert, V2, 2021.  
**Elecsys®** IGRA SARS-CoV-2 (200), Package Insert, V5, 2023.  
**Elecsys®** IGRA SARS-CoV-2 (300), Package Insert, V5, 2023.
2. **cobas®** 6800/8800 Systems Throughput and Workflow KPI calculations by Andreas Gisler Cobb, B et al. The **cobas®** 6800 8800 System a new era. ExpertReviewofMolecularDiagnostics2017.  
**cobas®** SARS-CoV-2 Qualitative Nucleic acid test for use on the **cobas®** 5800/6800/8800 Systems, Package Insert, V2, 2022.  
**cobas®** SARS-CoV-2 & Influenza A/B v2 Qualitative nucleic acid test for use on the **cobas®** 5800/6800/8800 Systems, Package Insert, V1, 2023.  
**cobas®** SARS-CoV-2 Duo Qualitative & Quantitative assay for use on the **cobas®** 5800/6800/8800 Systems, Package Insert, V1, 2023.
3. ePlex Respiratory Pathogen Panel 2, EUA, Package Insert, 2021.
4. **cobas®** SARS-CoV-2 Nucleic acid test for use on the **cobas®** liat system, Package Insert V03, Pleasanton, CA; Roche Molecular Systems, Inc., 2023.  
**cobas®** SARS-CoV-2 & Influenza A/B Nucleic acid test, Package Insert V01, Pleasanton, CA, Roche Molecular Systems, Inc. 2020.  
**cobas®** Influenza A/B & RSV [package insert], Pleasanton, CA; Roche Molecular Systems, Inc., 2021.  
**cobas®** Strep A [package insert V4], Pleasanton, CA; Roche Molecular Systems, Inc., 2020.  
**cobas®** Cdiff Nucleic acid test for use on the **cobas®** liat system, CE-IVD Package Insert V04, Pleasanton, CA; Roche Molecular Systems, Inc., 2022.
5. **cobas® eplex** respiratory pathogen panel 2, EUA, Package Insert, Rev. I, 2024.  
**cobas® eplex** respiratory pathogen panel 2, CEIVD, Package Insert, Rev. F, 2024.
6. Roche Molecular Systems Comparison, Carvalho, March 2024  
**cobas®** SARS-CoV-2 Qualitative Nucleic acid test for use on the **cobas®** 5800/6800/8800 Systems, Package Insert, V2, 2022  
**cobas®** SARS-CoV-2 & Influenza A/B v2 Qualitative nucleic acid test for use on the **cobas®** 5800/6800/8800 Systems, Package Insert, V1, 2023.  
**cobas®** SARS-CoV-2 Duo Qualitative & Quantitative assay for use on the **cobas®** 5800/6800/8800 Systems, Package Insert, V1, 2023.

The **cobas® liat** system is available in select markets.

COBAS, EPLEX and LIAT are trademarks of Roche. All other trademarks are the property of their respective owners.

© 2024 Roche Molecular Systems, Inc

### Published by:

Roche Molecular Systems  
4300 Hacienda Drive  
Pleasanton, CA 94588 USA

[diagnostics.roche.com](https://diagnostics.roche.com)